focus -WSS

focus

author：explore 2025-09-29 19:28:39 - browse：3

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Pig kidney works a record two months in donated body

hotspot

WSS

How medical schools plan to diversify without affirmative action

Private equity could exacerbate cardiology's overuse problem, experts fear

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

IRA could hurt research into orphan drugs for rare diseases

Fatty liver disease was alleviated by Lilly’s ‘triple

UpToDate has a racism problem: Dr. Stanley Goldfarb

focus

focus

hotspot

In Memoriam: Notable people who died in 2023

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Alkermes shareholders re

FDA approves updated Covid vaccines

As demand for Covid shots wanes, Moderna seeks its next success

Undocumented workers face uncertainty as immigration law takes effect in Florida

Continuity nursing helped my family in our darkest PICU moments

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Duchenne breakthrough therapy leaves behind pioneering families

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

hotspot

The biotech scorecard for Q3: 15 stock

Telehealth for opioid use disorder is lifesaving

FDA approves updated Covid vaccines

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

STAT wants to know your pick for a great summer read or listen

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

Wikipedia

hotspot

hotspot